Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome
Authors:
- Sunni L. MumfordSMSunni L. Mumford
- Richard S. LegroRLRichard S. Legro
- William D. SchlaffWSWilliam D. Schlaff
Open Access
- 1 September 2016
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 101 (9) , 3288-3296
Abstract
Context: Anti-Müllerian hormone (AMH) reduces aromatase activity and sensitivity of follicles to FSH stimulation. Therefore, elevated serum AMH may indicate a higher threshold for response to ovulation induction in women with polycystic ovary syndrome (PCOS). Objective: This study sought to determine the association between AMH levels and ovulatory response to treatment among the women enrolled into the Pregnancy in PCOS II (PPCOS II) trial. Design and setting: This was a secondary analysis of data from a randomized clinical trial in academic health centers throughout the United States Participants: A total of 748 women age 18–40 years, with PCOS and measured AMH levels at baseline, were included in this study. Main Outcome Measures: Couples were followed for up to five treatment cycles to determine ovulation (midluteal serum progesterone > 5 ng/mL) and the dose required to achieve ovulation. Results: A lower mean AMH and AMH per follicle was observed among women who ovulated compared with women who never achieved ovulation during the study (geometric mean AMH, 5.54 vs 7.35 ng/mL; P = .0001; geometric mean AMH per follicle, 0.14 vs 0.18; P = .01) after adjustment for age, body mass index, T, and insulin level. As AMH levels increased, the dose of ovulation induction medication needed to achieve ovulation also increased. No associations were observed between antral follicle count and ovulation. Conclusions: These results suggest that high serum AMH is associated with a reduced response to ovulation induction among women with PCOS. Women with higher AMH levels may require higher doses of medication to achieve ovulation. High baseline serum AMH was associated with a reduced response to ovulation induction among women with PCOS; women with higher AMH levels may require higher doses of medication to achieve ovulation.Keywords
This publication has 64 references indexed in Scilit:
- Antimüllerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cellsFertility and Sterility, 2013
- The influence of circulating anti-Müllerian hormone on ovarian responsiveness to ovulation induction with gonadotrophins in women with polycystic ovarian syndrome: a pilot studyReproductive Biology and Endocrinology, 2013
- Correlation between three assay systems for anti-Müllerian hormone (AMH) determinationJournal of Assisted Reproduction and Genetics, 2012
- The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndromeContemporary Clinical Trials, 2012
- The impact of obesity on egg qualityJournal of Assisted Reproduction and Genetics, 2011
- Correlation of ovarian reserve tests with histologically determined primordial follicle numberFertility and Sterility, 2011
- Total Testosterone Assays in Women with Polycystic Ovary Syndrome: Precision and Correlation with HirsutismThe Journal of Clinical Endocrinology & Metabolism, 2010
- The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle countFertility and Sterility, 2009
- Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell cultureFertility and Sterility, 2008
- Ultrasound assessment of the polycystic ovary: international consensus definitionsHuman Reproduction Update, 2003